A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous Abbott Combination Study

Inclusion Criteria:

Main Inclusion: To be enrolled in this protocol, subjects must meet all of the following inclusion criteria:

• Subject must have experienced virologic failure as defined in a previous peginterferon alpha-2a-free Abbott direct acting anti-viral combination trial.
• Female subjects of childbearing potential must be willing to use two effective forms of birth control (not including oral contraceptives or contraceptives containing ethinyl estradiol) while receiving study drug and for 6 months (or per local ribavirin label) after stopping study drug, unless abstinent from sexual intercourse.
• Males must be surgically sterile or agree to practice two effective forms of birth control throughout the course of the study, starting with Study Day 1 and for 6 months (or per local ribavirin label) after the last dose of study drug, unless abstinent from sexual intercourse.
• Subject must be considered an appropriate candidate for peginterferon alpha-2a, ribavirin, ABT-450/r and ABT-267 therapy in the opinion of the investigator.
• Subject is infected with HCV genotype 1 at screening.

Exclusion Criteria:

• In subjects with a null or partial response to peginterferon alpha-2a/ribavirin treatment (at the time of enrollment into the previous Abbott direct acting antiviral combination study), the presence of variants relative to the appropriate prototypic reference sequence (H77 for 1a or Con1 for 1B) at any of the following amino acid positions: NS3 protease 155, 156, or 168; NS5A 28, 29, 30, 31, 32, 58, or 93.
• Females who are pregnant or plan to become pregnant, or breast-feeding, or males whose partners are pregnant or planning to become pregnant.
• Use of known inhibitors (e.g., ketoconazole) or inducers (e.g., phenobarbital, rifampin, carbamazepine, St. John's Wort) of CYP3A and OATP1B1 (e.g., cyclosporine) within 1 month prior to study drug administration.
• Use of any medications contraindicated for use with peginterferon alpha-2a, ribavirin or ritonavir within 2 weeks prior to study drug administration or 10 half-lives, whichever is longer. Prior to entering the study, subjects must be able to safely discontinue the contraindicated medication or switch to an acceptable alternative under supervision of the investigator.
• Discontinuation of antiviral therapy due to intolerance or a direct acting antiviral or ribavirin associated adverse event in a previous Abbott direct acting anti-viral combination study.